Emmanuel Brouillet, PhD - Publications

Affiliations: 
Pharmacology University of Paris-Sud 11 (Orsay) 

105 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Abjean L, Ben Haim L, Riquelme-Perez M, Gipchtein P, Derbois C, Palomares MA, Petit F, Hérard AS, Gaillard MC, Guillermier M, Gaudin-Guérif M, Aurégan G, Sagar N, Héry C, Dufour N, ... ... Brouillet E, et al. Reactive astrocytes promote proteostasis in Huntington's disease through the JAK2-STAT3 pathway. Brain : a Journal of Neurology. PMID 35298632 DOI: 10.1093/brain/awac068  0.37
2021 Niewiadomska-Cimicka A, Doussau F, Perot JB, Roux MJ, Keime C, Hache A, Piguet F, Novati A, Weber C, Yalcin B, Meziane H, Champy MF, Grandgirard E, Karam A, Messaddeq N, ... ... Brouillet E, et al. SCA7 mouse cerebellar pathology reveals preferential downregulation of key Purkinje cell-identity genes and shared disease signature with SCA1 and SCA2. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33888607 DOI: 10.1523/JNEUROSCI.1882-20.2021  0.302
2020 Pépin J, de Longprez L, Trovero F, Brouillet E, Valette J, Flament J. Complementarity of gluCEST and H-MRS for the study of mouse models of Huntington's disease. Nmr in Biomedicine. e4301. PMID 32198958 DOI: 10.1002/Nbm.4301  0.424
2020 Guillemaud O, Ceyzériat K, Saint-Georges T, Cambon K, Petit F, Ben Haim L, Carrillo-de Sauvage MA, Guillermier M, Bernier S, Hérard AS, Joséphine C, Bémelmans AP, Brouillet E, Hantraye P, Bonvento G, et al. Complex roles for reactive astrocytes in the triple transgenic mouse model of Alzheimer disease. Neurobiology of Aging. PMID 32171592 DOI: 10.1016/J.Neurobiolaging.2020.02.010  0.334
2020 Le Douce J, Maugard M, Veran J, Matos M, Jégo P, Vigneron PA, Faivre E, Toussay X, Vandenberghe M, Balbastre Y, Piquet J, Guiot E, Tran NT, Taverna M, Marinesco S, ... ... Brouillet E, et al. Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's Disease. Cell Metabolism. 31: 503-517.e8. PMID 32130882 DOI: 10.1016/J.Cmet.2020.02.004  0.303
2019 Cresto N, Gaillard MC, Gardier C, Gubinelli F, Diguet E, Bellet D, Legroux L, Mitja J, Auregan G, Guillermier M, Josephine C, Jan C, Dufour N, Joliot A, Hantraye P, ... ... Brouillet E, et al. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. Neurobiology of Disease. 104614. PMID 31605779 DOI: 10.1016/J.Nbd.2019.104614  0.415
2019 Brouillet E, Merienne K. What is gained or 'lost in translation' in Huntington's disease. Brain : a Journal of Neurology. 142: 2900-2902. PMID 31560061 DOI: 10.1093/Brain/Awz274  0.334
2019 Gary C, Lam S, Hérard AS, Koch JE, Petit F, Gipchtein P, Sawiak SJ, Caillierez R, Eddarkaoui S, Colin M, Aujard F, Deslys JP, Brouillet E, Buée L, et al. Encephalopathy induced by Alzheimer brain inoculation in a non-human primate. Acta Neuropathologica Communications. 7: 126. PMID 31481130 DOI: 10.1186/S40478-019-0771-X  0.422
2019 Ligneul C, Palombo M, Hernández-Garzón E, Carrillo-de Sauvage MA, Flament J, Hantraye P, Brouillet E, Bonvento G, Escartin C, Valette J. Diffusion-weighted magnetic resonance spectroscopy enables cell-specific monitoring of astrocyte reactivity in vivo. Neuroimage. 191: 457-469. PMID 30818026 DOI: 10.1016/J.Neuroimage.2019.02.046  0.328
2018 Ceyzériat K, Ben Haim L, Denizot A, Pommier D, Matos M, Guillemaud O, Palomares MA, Abjean L, Petit F, Gipchtein P, Gaillard MC, Guillermier M, Bernier S, Gaudin M, Aurégan G, ... ... Brouillet E, et al. Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer's disease. Acta Neuropathologica Communications. 6: 104. PMID 30322407 DOI: 10.1186/S40478-018-0606-1  0.393
2018 Cresto N, Gardier C, Gubinelli F, Gaillard MC, Liot G, West AB, Brouillet E. The Unlikely Partnership Between LRRK2 and α-Synuclein in Parkinson's Disease. The European Journal of Neuroscience. PMID 30269383 DOI: 10.1111/Ejn.14182  0.359
2018 Galvan L, Francelle L, Gaillard MC, de Longprez L, Carrillo-de Sauvage MA, Liot G, Cambon K, Stimmer L, Luccantoni S, Flament J, Valette J, de Chaldée M, Auregan G, Guillermier M, Joséphine C, ... ... Brouillet E, et al. The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin. Brain : a Journal of Neurology. PMID 29534157 DOI: 10.1093/Brain/Awy057  0.782
2018 Abjean L, Haim LB, Sauvage MAC, Hérard A, Derbois C, Petit F, Gipstein P, Guillermier M, Gaudin M, Bernier S, Dufour N, Bémelmans A, Deleuze J, Hantraye P, Bonvento G, ... ... Brouillet E, et al. A42 Reactive astrocytes promote proteostasis in huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.40  0.432
2017 d'Orange M, Aurégan G, Cheramy D, Gaudin-Guérif M, Lieger S, Guillermier M, Stimmer L, Joséphine C, Hérard AS, Gaillard MC, Petit F, Kiessling MC, Schmitz C, Colin M, Buée L, ... ... Brouillet E, et al. Potentiating tangle formation reduces acute toxicity of soluble tau species in the rat. Brain : a Journal of Neurology. PMID 29253129 DOI: 10.1093/Brain/Awx342  0.394
2017 Merienne N, Vachey G, de Longprez L, Meunier C, Zimmer V, Perriard G, Canales M, Mathias A, Herrgott L, Beltraminelli T, Maulet A, Dequesne T, Pythoud C, Rey M, Pellerin L, ... Brouillet E, et al. The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. Cell Reports. 20: 2980-2991. PMID 28930690 DOI: 10.1016/J.Celrep.2017.08.075  0.388
2017 Bonvento G, Valette J, Flament J, Mochel F, Brouillet E. Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 271678X17697989. PMID 28276944 DOI: 10.1177/0271678X17697989  0.384
2017 Le Gras S, Keime C, Anthony A, Lotz C, De Longprez L, Brouillet E, Cassel JC, Boutillier AL, Merienne K. Altered enhancer transcription underlies Huntington's disease striatal transcriptional signature. Scientific Reports. 7: 42875. PMID 28225006 DOI: 10.1038/Srep42875  0.46
2017 Francelle L, Lotz C, Outeiro T, Brouillet E, Merienne K. Contribution of Neuroepigenetics to Huntington's Disease. Frontiers in Human Neuroscience. 11: 17. PMID 28194101 DOI: 10.3389/Fnhum.2017.00017  0.769
2016 Galan-Rodriguez B, Martin E, Brouillet E, Déglon N, Betuing S, Caboche J. Coupling of d2R short but not d2R Long receptor isoform to the Rho/Rock signaling pathway renders striatal neurons vulnerable to mutant huntingtin. The European Journal of Neuroscience. PMID 27717053 DOI: 10.1111/Ejn.13415  0.424
2016 Liot G, Valette J, Pépin J, Flament J, Brouillet E. Energy defects in Huntington's disease: Why "in vivo" evidence matters. Biochemical and Biophysical Research Communications. PMID 27639641 DOI: 10.1016/J.Bbrc.2016.09.065  0.451
2016 Pépin J, Francelle L, Carrillo-de Sauvage MA, de Longprez L, Gipchtein P, Cambon K, Valette J, Brouillet E, Flament J. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease. Neuroimage. 139: 53-64. PMID 27318215 DOI: 10.1016/J.Neuroimage.2016.06.023  0.775
2016 Flament J, Pépin J, Francelle L, Sauvage MC, Longprez Ld, Gipchtein P, Cambon K, Valette J, Brouillet E. B40 In vivo imaging of brain glutamate defects in a knock-in mouse model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.71  0.745
2016 Ceyzeriat K, Haim LB, Saint-Georges T, Petit F, Houitte D, Guillermier M, Berniard A, Mitja J, Josephine C, Hantraye P, Brouillet E, Cambon K, Dhenain M, Bonvento G, Escartin C. Specific Inhibition Of Astrocyte Reactivity Improves Some Disease Outcomes In Alzheimer'S Disease Mice Alzheimers & Dementia. 12: 242. DOI: 10.1016/J.Jalz.2016.06.433  0.352
2016 Douce JL, Veran J, Jego P, Faivre E, Herard A, Taverna M, Brouillet E, Toussay X, Cauli B, Oliet S, Panatier A, Bonvento G. Deficits Of Synaptic Plasticity In A Mouse Model Of Alzheimer'S Disease Are Linked To Astrocytic L-Serine Production Alzheimers & Dementia. 12: 1043. DOI: 10.1016/J.Jalz.2016.06.2167  0.32
2015 Rocher AB, Gubellini P, Merienne N, Boussicault L, Petit F, Gipchtein P, Jan C, Hantraye P, Brouillet E, Bonvento G. Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease. Neurobiology of Disease. PMID 26626081 DOI: 10.1016/J.Nbd.2015.10.016  0.425
2015 Carrillo-de Sauvage MA, Flament J, Bramoulle Y, Ben Haim L, Guillermier M, Berniard A, Aurégan G, Houitte D, Brouillet E, Bonvento G, Hantraye P, Valette J, Escartin C. The neuroprotective agent CNTF decreases neuronal metabolites in the rat striatum: an in vivo multimodal magnetic resonance imaging study. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 35: 917-21. PMID 25833344 DOI: 10.1038/Jcbfm.2015.48  0.433
2015 Ben Haim L, Ceyzériat K, Carrillo-de Sauvage MA, Aubry F, Auregan G, Guillermier M, Ruiz M, Petit F, Houitte D, Faivre E, Vandesquille M, Aron-Badin R, Dhenain M, Déglon N, Hantraye P, ... Brouillet E, et al. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 2817-29. PMID 25673868 DOI: 10.1523/Jneurosci.3516-14.2015  0.407
2015 Francelle L, Galvan L, Gaillard MC, Petit F, Bernay B, Guillermier M, Bonvento G, Dufour N, Elalouf JM, Hantraye P, Déglon N, de Chaldée M, Brouillet E. The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. Neurobiology of Aging. 36: 1601.e7-16. PMID 25619660 DOI: 10.1016/J.Neurobiolaging.2014.11.014  0.749
2015 Francelle L, Galvan L, Gaillard MC, Guillermier M, Houitte D, Bonvento G, Petit F, Jan C, Dufour N, Hantraye P, Elalouf JM, De Chaldée M, Déglon N, Brouillet E. Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease. Human Molecular Genetics. 24: 1563-73. PMID 25398949 DOI: 10.1093/Hmg/Ddu571  0.783
2015 Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, Demeyer D, Sergeant N, Gerhardt E, Brouillet E, Buée L, Outeiro TF. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Human Molecular Genetics. 24: 76-85. PMID 25143394 DOI: 10.1093/Hmg/Ddu421  0.743
2014 Francelle L, Galvan L, Brouillet E. Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease. Frontiers in Cellular Neuroscience. 8: 295. PMID 25309327 DOI: 10.3389/Fncel.2014.00295  0.78
2014 Boussicault L, Hérard AS, Calingasan N, Petit F, Malgorn C, Merienne N, Jan C, Gaillard MC, Lerchundi R, Barros LF, Escartin C, Delzescaux T, Mariani J, Hantraye P, Beal MF, ... Brouillet E, et al. Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 34: 1500-10. PMID 24938402 DOI: 10.1038/Jcbfm.2014.110  0.579
2014 Brouillet E. The 3-NP Model of Striatal Neurodegeneration. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. 67: 9.48.1-9.48.14. PMID 24723322 DOI: 10.1002/0471142301.Ns0948S67  0.384
2014 Facchinetti P, Dorard E, Contremoulins V, Gaillard MC, Déglon N, Sazdovitch V, Guihenneuc-Jouyaux C, Brouillet E, Duyckaerts C, Allinquant B. SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients. Neurobiology of Aging. 35: 958-68. PMID 24262202 DOI: 10.1016/J.Neurobiolaging.2013.08.039  0.312
2013 Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Déglon N, ... ... Brouillet E, et al. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Human Molecular Genetics. 22: 3869-82. PMID 23720495 DOI: 10.1093/Hmg/Ddt242  0.702
2013 Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, Francelle L, Aurégan G, Guillermier M, Cailleret M, Viegas P, Nicoleau C, Martinat C, Brouillet E, Cattaneo E, et al. High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. Stem Cells (Dayton, Ohio). 31: 1816-28. PMID 23712629 DOI: 10.1002/Stem.1430  0.757
2012 Delzor A, Dufour N, Petit F, Guillermier M, Houitte D, Auregan G, Brouillet E, Hantraye P, Déglon N. Restricted transgene expression in the brain with cell-type specific neuronal promoters. Human Gene Therapy Methods. 23: 242-54. PMID 22934828 DOI: 10.1089/Hgtb.2012.073  0.446
2012 Chaumeil MM, Valette J, Baligand C, Brouillet E, Hantraye P, Bloch G, Gaura V, Rialland A, Krystkowiak P, Verny C, Damier P, Remy P, Bachoud-Levi AC, Carlier P, Lebon V. pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 771-9. PMID 22373643 DOI: 10.1038/Jcbfm.2012.15  0.303
2012 Galvan L, Lepejová N, Gaillard MC, Malgorn C, Guillermier M, Houitte D, Bonvento G, Petit F, Dufour N, Héry P, Gérard M, Elalouf JM, Déglon N, Brouillet E, de Chaldée M. Capucin does not modify the toxicity of a mutant Huntingtin fragment in vivo. Neurobiology of Aging. 33: 1845.e5-6. PMID 22365050 DOI: 10.1016/J.Neurobiolaging.2012.01.009  0.469
2012 Mochel F, Durant B, Meng X, O'Callaghan J, Yu H, Brouillet E, Wheeler VC, Humbert S, Schiffmann R, Durr A. Early alterations of brain cellular energy homeostasis in Huntington disease models. The Journal of Biological Chemistry. 287: 1361-70. PMID 22123819 DOI: 10.1074/Jbc.M111.309849  0.396
2011 Shin M, Jan C, Jacquard C, Jarraya B, Callebert J, Launay JM, Hantraye P, Remy P, Palfi S, Brouillet E. Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration. Neurobiology of Aging. 32: 2100-2. PMID 20018410 DOI: 10.1016/J.Neurobiolaging.2009.11.015  0.364
2010 Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Déglon N, Ferrante RJ, Bonvento G. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Human Molecular Genetics. 19: 3053-67. PMID 20494921 DOI: 10.1093/Hmg/Ddq212  0.447
2010 Escartin C, Brouillet E. The Nrf2 pathway as a potential therapeutic target for Huntington disease A commentary on "Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease". Free Radical Biology & Medicine. 49: 144-6. PMID 20399852 DOI: 10.1016/J.Freeradbiomed.2010.04.009  0.393
2010 Alves S, Nascimento-Ferreira I, Dufour N, Hassig R, Auregan G, Nóbrega C, Brouillet E, Hantraye P, Pedroso de Lima MC, Déglon N, de Almeida LP. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Human Molecular Genetics. 19: 2380-94. PMID 20308049 DOI: 10.1093/Hmg/Ddq111  0.385
2010 Cleren C, Calingasan NY, Starkov A, Jacquard C, Chen J, Brouillet E, Beal MF. Promethazine protects against 3-nitropropionic acid-induced neurotoxicity. Neurochemistry International. 56: 208-12. PMID 19852992 DOI: 10.1016/J.Neuint.2009.10.006  0.555
2010 Damiano M, Galvan L, Déglon N, Brouillet E. Mitochondria in Huntington's disease. Biochimica Et Biophysica Acta. 1802: 52-61. PMID 19682570 DOI: 10.1016/J.Bbadis.2009.07.012  0.686
2009 Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Hérard AS, Day DM, Brouillet E, Kingsman SM, Hantraye P, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science Translational Medicine. 1: 2ra4. PMID 20368163 DOI: 10.1126/Scitranslmed.3000130  0.434
2009 Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, Déglon N. Sustained effects of nonallele-specific Huntingtin silencing. Annals of Neurology. 65: 276-85. PMID 19334076 DOI: 10.1002/Ana.21569  0.387
2009 Diguet E, Petit F, Escartin C, Cambon K, Bizat N, Dufour N, Hantraye P, Déglon N, Brouillet E. Normal aging modulates the neurotoxicity of mutant huntingtin. Plos One. 4: e4637. PMID 19247483 DOI: 10.1371/Journal.Pone.0004637  0.403
2009 Bernay B, Gaillard MC, Guryca V, Emadali A, Kuhn L, Bertrand A, Detraz I, Carcenac C, Savasta M, Brouillet E, Garin J, Elalouf JM. Discovering new bioactive neuropeptides in the striatum secretome using in vivo microdialysis and versatile proteomics. Molecular & Cellular Proteomics : McP. 8: 946-58. PMID 19164277 DOI: 10.1074/Mcp.M800501-Mcp200  0.349
2009 Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia. 57: 1154-67. PMID 19115380 DOI: 10.1002/Glia.20838  0.37
2009 Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, Aebischer P, Luthi-Carter R, Déglon N. Implication of the JNK pathway in a rat model of Huntington's disease. Experimental Neurology. 215: 191-200. PMID 19022249 DOI: 10.1016/J.Expneurol.2008.10.008  0.424
2009 Colin A, Faideau M, Dufour N, Auregan G, Hassig R, Andrieu T, Brouillet E, Hantraye P, Bonvento G, Déglon N. Engineered lentiviral vector targeting astrocytes in vivo. Glia. 57: 667-79. PMID 18942755 DOI: 10.1002/Glia.20795  0.4
2009 Galvan L, Brouillet E. Rhes, a protein with selective expression in the striatum, plays a major role in Huntington's disease pathogenesis Future Neurology. 4: 697-701. DOI: 10.2217/Fnl.09.46  0.434
2008 Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, Déglon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. Plos One. 3: e3341. PMID 18841197 DOI: 10.1371/Journal.Pone.0003341  0.365
2008 Alves S, Régulier E, Nascimento-Ferreira I, Hassig R, Dufour N, Koeppen A, Carvalho AL, Simões S, de Lima MC, Brouillet E, Gould VC, Déglon N, de Almeida LP. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Human Molecular Genetics. 17: 2071-83. PMID 18385100 DOI: 10.1093/Hmg/Ddn106  0.463
2008 Charvin D, Roze E, Perrin V, Deyts C, Betuing S, Pagès C, Régulier E, Luthi-Carter R, Brouillet E, Déglon N, Caboche J. Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiology of Disease. 29: 22-9. PMID 17905594 DOI: 10.1016/J.Nbd.2007.07.028  0.457
2007 Escartin C, Boyer F, Bemelmans AP, Hantraye P, Brouillet E. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats. Neuroscience Letters. 425: 167-72. PMID 17868993 DOI: 10.1016/J.Neulet.2007.08.031  0.44
2007 Escartin C, Pierre K, Colin A, Brouillet E, Delzescaux T, Guillermier M, Dhenain M, Déglon N, Hantraye P, Pellerin L, Bonvento G. Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 7094-104. PMID 17611262 DOI: 10.1523/Jneurosci.0174-07.2007  0.396
2007 García-Martínez JM, Pérez-Navarro E, Xifró X, Canals JM, Díaz-Hernández M, Trioulier Y, Brouillet E, Lucas JJ, Alberch J. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. Journal of Neuroscience Research. 85: 2756-69. PMID 17387706 DOI: 10.1002/Jnr.21258  0.41
2006 Escartin C, Brouillet E, Gubellini P, Trioulier Y, Jacquard C, Smadja C, Knott GW, Kerkerian-Le Goff L, Déglon N, Hantraye P, Bonvento G. Ciliary neurotrophic factor activates astrocytes, redistributes their glutamate transporters GLAST and GLT-1 to raft microdomains, and improves glutamate handling in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 5978-89. PMID 16738240 DOI: 10.1523/Jneurosci.0302-06.2006  0.394
2006 Arango M, Holbert S, Zala D, Brouillet E, Pearson J, Régulier E, Thakur AK, Aebischer P, Wetzel R, Déglon N, Néri C. CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 4649-59. PMID 16641246 DOI: 10.1523/Jneurosci.5409-05.2006  0.365
2006 Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, Cheetham ME, Néri C, Alberch J, Brouillet E, Saudou F, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. The Journal of Clinical Investigation. 116: 1410-24. PMID 16604191 DOI: 10.1172/Jci27607  0.397
2006 Jacquard C, Trioulier Y, Cosker F, Escartin C, Bizat N, Hantraye P, Cancela JM, Bonvento G, Brouillet E. Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1021-3. PMID 16571773 DOI: 10.1096/Fj.05-5085Fje  0.378
2005 Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry. 95: 1521-40. PMID 16300642 DOI: 10.1111/j.1471-4159.2005.03515.x  0.344
2005 Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, Déglon N. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiology of Disease. 20: 785-98. PMID 16006135 DOI: 10.1016/J.Nbd.2005.05.017  0.442
2005 Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K, Galas MC, Tenenbaum L, Déglon N, Popoli P, Minghetti L, Brouillet E, Brotchi J, Levivier M, Schiffmann SN, et al. Minocycline in phenotypic models of Huntington's disease. Neurobiology of Disease. 18: 206-17. PMID 15649711 DOI: 10.1016/j.nbd.2004.09.017  0.336
2005 Deglon N, Zala D, Benchoua A, Aebischer P, Zurn AD, Brouillet E. 953. Progressive and Selective Striatal Degeneration in Primary Neuronal Cultures Using Lentiviral Vector Coding Mutant Huntingtin Fragment Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.496  0.44
2004 Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport. 15: 2375-9. PMID 15640759 DOI: 10.1097/00001756-200410250-00015  0.373
2004 Yang L, Sugama S, Mischak RP, Kiaei M, Bizat N, Brouillet E, Joh TH, Beal MF. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiology of Disease. 17: 250-9. PMID 15474362 DOI: 10.1016/J.Nbd.2004.07.021  0.708
2004 Escartin C, Boyer F, Bemelmans AP, Hantraye P, Brouillet E. Insulin growth factor-1 protects against excitotoxicity in the rat striatum. Neuroreport. 15: 2251-4. PMID 15371744 DOI: 10.1097/00001756-200410050-00022  0.351
2004 Galas MC, Bizat N, Cuvelier L, Bantubungi K, Brouillet E, Schiffmann SN, Blum D. Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiology of Disease. 15: 152-9. PMID 14751780 DOI: 10.1016/j.nbd.2003.09.013  0.308
2003 Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernández-Ruiz J. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport. 14: 813-6. PMID 12858038 DOI: 10.1097/00001756-200305060-00007  0.412
2003 de Chaldée M, Gaillard MC, Bizat N, Buhler JM, Manzoni O, Bockaert J, Hantraye P, Brouillet E, Elalouf JM. Quantitative assessment of transcriptome differences between brain territories. Genome Research. 13: 1646-53. PMID 12840043 DOI: 10.1101/Gr.1173403  0.32
2003 Bizat N, Hermel JM, Boyer F, Jacquard C, Créminon C, Ouary S, Escartin C, Hantraye P, Kajewski S, Brouillet E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 5020-30. PMID 12832525 DOI: 10.1523/Jneurosci.23-12-05020.2003  0.421
2002 Henry PG, Lebon V, Vaufrey F, Brouillet E, Hantraye P, Bloch G. Decreased TCA cycle rate in the rat brain after acute 3-NP treatment measured by in vivo 1H-[13C] NMR spectroscopy. Journal of Neurochemistry. 82: 857-66. PMID 12358791 DOI: 10.1046/J.1471-4159.2002.01006.X  0.307
2002 Mittoux V, Ouary S, Monville C, Lisovoski F, Poyot T, Conde F, Escartin C, Robichon R, Brouillet E, Peschanski M, Hantraye P. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 4478-86. PMID 12040055 DOI: 10.1523/Jneurosci.22-11-04478.2002  0.408
2002 Garcia M, Vanhoutte P, Pages C, Besson MJ, Brouillet E, Caboche J. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 2174-84. PMID 11896157 DOI: 10.1523/Jneurosci.22-06-02174.2002  0.431
2000 Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, Poyot T, Bloch J, Deglon N, Ouary S, Nimchinsky EA, Brouillet E, Hof PR, Peschanski M, Aebischer P, Hantraye P. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Human Gene Therapy. 11: 1177-87. PMID 10834619 DOI: 10.1089/10430340050015220  0.427
2000 Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Condé F, Bloch G, Hantraye P. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 20: 789-99. PMID 10826529 DOI: 10.1097/00004647-200005000-00005  0.428
2000 Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 11: 211-3. PMID 10683860 DOI: 10.1097/00001756-200001170-00041  0.485
1999 Brouillet E, Condé F, Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Progress in Neurobiology. 59: 427-68. PMID 10515664 DOI: 10.1016/S0301-0082(99)00005-2  0.597
1999 Dautry C, Condé F, Brouillet E, Mittoux V, Beal MF, Bloch G, Hantraye P. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiology of Disease. 6: 259-68. PMID 10448053 DOI: 10.1006/Nbdi.1999.0244  0.533
1999 Ferrante RJ, Hantraye P, Brouillet E, Beal MF. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Research. 823: 177-82. PMID 10095024 DOI: 10.1016/S0006-8993(99)01166-X  0.563
1998 Palfi S, Condé F, Riche D, Brouillet E, Dautry C, Mittoux V, Chibois A, Peschanski M, Hantraye P. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nature Medicine. 4: 963-6. PMID 9701252 DOI: 10.1038/Nm0898-963  0.382
1998 Brouillet E, Guyot MC, Mittoux V, Altairac S, Condé F, Palfi S, Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. Journal of Neurochemistry. 70: 794-805. PMID 9453576 DOI: 10.1046/J.1471-4159.1998.70020794.X  0.398
1997 Guyot MC, Palfi S, Stutzmann JM, Mazière M, Hantraye P, Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience. 81: 141-9. PMID 9300407 DOI: 10.1016/S0306-4522(97)00192-9  0.365
1997 Palfi S, Riche D, Brouillet E, Guyot MC, Mary V, Wahl F, Peschanski M, Stutzmann JM, Hantraye P. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Experimental Neurology. 146: 135-41. PMID 9225746 DOI: 10.1006/Exnr.1997.6520  0.382
1997 Guyot MC, Hantraye P, Dolan R, Palfi S, Maziére M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 79: 45-56. PMID 9178864 DOI: 10.1016/S0306-4522(96)00602-1  0.319
1996 Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Medicine. 2: 1017-21. PMID 8782460 DOI: 10.1038/nm0996-1017  0.51
1996 Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 3019-25. PMID 8622131 DOI: 10.1523/Jneurosci.16-09-03019.1996  0.528
1996 Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 16: 450-61. PMID 8621749 DOI: 10.1097/00004647-199605000-00011  0.666
1995 Brouillet E, Hantraye P. Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Current Opinion in Neurology. 8: 469-73. PMID 8845934 DOI: 10.1097/00019052-199512000-00014  0.389
1995 Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proceedings of the National Academy of Sciences of the United States of America. 92: 7105-9. PMID 7624378 DOI: 10.1073/Pnas.92.15.7105  0.596
1994 Brouillet E, Henshaw DR, Schulz JB, Beal MF. Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. Neuroscience Letters. 177: 58-62. PMID 7824183 DOI: 10.1016/0304-3940(94)90044-2  0.556
1994 Brouillet E, Hyman BT, Jenkins BG, Henshaw DR, Schulz JB, Sodhi P, Rosen BR, Beal MF. Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Experimental Neurology. 129: 175-82. PMID 7525331 DOI: 10.1006/Exnr.1994.1159  0.557
1993 Brouillet E, Beal MF. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport. 4: 387-90. PMID 8499594 DOI: 10.1097/00001756-199304000-00011  0.454
1993 Brouillet EP, Shinobu L, McGarvey U, Hochberg F, Beal MF. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Experimental Neurology. 120: 89-94. PMID 8477830 DOI: 10.1006/exnr.1993.1042  0.74
1993 Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, Beal MF. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. Journal of Neurochemistry. 60: 356-9. PMID 8417157 DOI: 10.1111/J.1471-4159.1993.Tb05859.X  0.502
1993 Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiology of Aging. 14: 295-301. PMID 8103573 DOI: 10.1016/0197-4580(93)90114-Q  0.624
1993 Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 13: 4181-92. PMID 7692009  0.637
1993 Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. Journal of Neurochemistry. 61: 1147-50. PMID 7689641 DOI: 10.1111/J.1471-4159.1993.Tb03633.X  0.571
1993 Beal M, Brouillet E, Jenkins B, Ferrante R, Kowall N, Miller J, Storey E, Srivastava R, Rosen B, Hyman B. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid The Journal of Neuroscience. 13: 4181-4192. DOI: 10.1523/Jneurosci.13-10-04181.1993  0.767
1992 Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. Journal of Neurochemistry. 58: 1975-8. PMID 1560246 DOI: 10.1111/J.1471-4159.1992.Tb10080.X  0.649
1990 Yamaguchi T, Kunimoto M, Pappata S, Chavoix C, Brouillet E, Riche D, Mazière M, Naquet R, MacKenzie ET, Baron JC. Effects of unilateral lesion of the nucleus basalis of Meynert on brain glucose utilization in callosotomized baboons: a PET study. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 10: 618-23. PMID 2384534 DOI: 10.1038/Jcbfm.1990.113  0.302
Show low-probability matches.